Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 219 participants.

Also called NCT03014479

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 219 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03014479
  • WHO UTN U1111-1189-9256
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03014479. Randomized; no masking; primary purpose treatment. Start 2017-02-18 (actual); primary completion 2017-10-21 (actual). Results posted on 2019-02-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus
Acronym
TRENDS
Intervention (Drug)
Trelagliptin
Intervention (Drug)
Daily DPP-4 inhibitor
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct03014479
Content hash
34cb303a3a1152096556f9db1ef365f78f470591a12e3340cef876262ea07317